Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2018
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROTECT
- 06 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2011 Additional lead trial investigators identified as reported by ClinicalTrials.gov record (Extension trial: NCT01338012).
- 26 Oct 2011 Planned End Date changed from 1 Dec 2003 to 1 Aug 2006 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History